Spire Inc. (SR)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

74.99

+1.74

(+2.38%)

At close: 04:00PM EDT

74.99

+0.04

(+0.05%)

After hours:

04:02PM EDT

Advertisement

I
Hoping for some news on Sorrento in the coming days. Taken from NY Post article today “We’re hopeful that, with some of the breakthrough technology on therapeutics, that we will be able to announce some new therapies in the coming days,” Meadows said in an interview with ABC News.

https://nypost.com/2020/07/26/new-covid-19-treatments-may-be-days-away-wh-chief-of-staff/
White House Chief of Staff Mark Meadows on Sunday said he was “hopeful” that within days there will be an announcement on new treatments for COVID-19. “We’re hopeful that, w…
White House Chief of Staff Mark Meadows on Sunday said he was “hopeful” that within days there will be an announcement on new treatments for COVID-19. “We’re hopeful that, w…
nypost.com
Bullish
Y
Bought some shares of Spire at $60.50 the other day. Very low PE ratio and a nice dividend. I think this has a lot of upward mobility and will provide some nice cashflow to boot.
W
A better buy at 62 :P
T
I bought this stock in May 2012 for around $38/share when it was known as LeClede Gas. My dividend is inching up near 6%. Every year like clockwork, they have raised the dividend. Unless something drastic happens with this company, I'll probably be holding this until I die.
J
Good, stable, NYSE company.
Bullish
Y
SR-PA reached a 52 Week low at 23.85
Y
SR reached a new 52 Week Low at 61.00
D
A steady propane/NG pipeline and storage company with decent dividend. GLTA
a
Is this decline result of pipeline shutdown?
Y
SR-PA reached an all time low at 24.80
s
I'm new to this stock. Where is the bottom? I'm going to buy once it hits as low as it can be. Is there a traditional season where the stock is high? nice divys..
M
Another D44 summary of the Sorrento programs ....

"Look for one PR followed by another elevating Sorrento shares to new successive highs in the next several months.
Not only are investors awaiting EUA approval of it's COVIDTRACK test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus. Investors are also waiting on positive news for approval of their antibody cocktail "COVI-SHIELD" STI-1499..the company's preventative treatment.

NIH Clinical trial listing posted 6/25 & 7/1 waiting for FDA approvals to initiate..

NEW
Not yet recruiting
Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19

Condition
Covid-19
Interventions:
Biological: STI-1499
Other: Standard of Care
Drug: Placebo
Locations:

NEW
Not yet recruiting
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19

Condition
Covid-19
Interventions:
Drug: Abivertinib
Other: Standard of Care
Locations:

Longer term..

The future of Sorrento lies in it's core Oncology & Pain programmes. Core programs listed in order of importance to the company. COVID is the most recent addition to the company's platforms. As you can see below from Sorrento's extensive research.. cancer & pain
are core to the company's
programmes..

Immuno-Oncology
Key Programs

*CART (MultipleMyeloma)
Ph I

*CD38 DAR-T (Multiple Myeloma)
Preclinical

*CD38 ADC (Amyloidosis)
Ph I

*Seprehvir™ (Solid Tumors)
Ph I

Pain Key Programs

*RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain)
Ph II

*RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA)
Ph II

*RTX (resiniferatoxin) Intra-articular route
(TKR Deferment)
Preclinical

Lymphatic DeliveryKey Programs

*Sofusa® anti-TNF (Autoimmune)
Preclinical

*Sofusa® anti-PD-1
(ImmunoOncolog)
Preclinical

COVID-19 Programs
Key Programs

*COVIDGUARD
Preclinical

*COVIDSHIELD
Preclinical

*COVIDTRAP
Preclinical

Sorrento's many Partnerships & Subsidiaries

SCILEX
58% ownership stake.
IPO pending 2020

BIOSERV
100% owned subsidiary.

CONCORTIS/ LEVENA 100% owned subsidiary

ARK ANIMAL HEALTH
100% owned subsidiary

YUHAN
35% ownership of ImmuneOncia JV

LEE PHARM
Sorrento licensee. Collaboration

CELULARITY
25% ownership stake
JDA ( joint development agreement) $5 ml

MABPHARM
Collaboration & development

https://sorrentotherapeutics.com/partnership/
Partner: Asset Type: Partner Background: Partnership Details: Partner: Asset Type: Immuno-Oncology Partner Background: Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago Partnership Details: Joint Ventu
Partner: Asset Type: Partner Background: Partnership Details: Partner: Asset Type: Immuno-Oncology Partner Background: Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago Partnership Details: Joint Ventu
sorrentotherapeutics.com
B
Nice pipeline of products. CovidTrap is in line with research from UCSF that is all over the news now. Is this one in the same? What about patents? See these articles:
https://www.biorxiv.org/content/10.1101/2020.08.08.238469v1

http://walterlab.ucsf.edu/publication/1472/an-ultra-high-affinity-synthetic-nanobody-blocks-sars-cov-2-infection-by-locking-spike-into-an-inactive-conformation/

https://spectrum.ieee.org/the-human-os/biomedical/devices/covid19-aeronabs

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430568.1/
D
Nice price recovery on a low volume day. Just holding and DRIP
Bullish
R
$SR will provide an update on its growth initiatives as well as recent performance and developments. Here is the link for more info http://crweworld.com/article/news-provided-by-pr-newswire/303039/spire-to-present-at-aga-financial-forum
N
$TNP conversation
Most significant #oil #tanker spot movements today:

#VLCC -7% to $57k/d
#Aframax +13% to $43k/d
#LR2 -14% to $15.6k/d
#SR -25% to $18.0k/d
N
$TNP conversation
Most significant #oil #tanker spot movements today:

#VLCC -7% to $57k/d
#Aframax +13% to $43k/d
#LR2 -14% to $15.6k/d
#SR -25% to $18.0k/d
G
I’m buying.
D
Nice close for a Friday, 1.5 times average volume. GLTA, enjoy your first full weekend of summer
Bullish
Y
SR-PA reached a 52 Week low at 24.52